Michael Heffernan

Michael Thomas Heffernan founded Collegium Pharmaceutical, Inc. in 2002, where he worked as Chairman from 2024 to 2025, PreCision Dermatology, Inc. in 2010, where he worked as Director from 2010 to 2014, Clinical Studies Ltd. in 1995, where he worked as President & Chief Executive Officer from 1995 to 1997, Avenge Bio, Inc. in 2019, where he worked as President, Chief Executive Officer & Director from 2019 to 2024, and Onset Dermatologics LLC in 2005, where he worked as President & Chief Executive Officer from 2005 to 2011.
Mr. Heffernan also currently works at NMD Pharma A, as Chairman from 2023, Indalo Therapeutics, Inc., as Chairman from 2019, Avalo Therapeutics, Inc., as Chairman from 2025, AAVantgarde Bio Srl, as Chairman, Biohaven Ltd., as Lead Independent Director from 2020, enGene Therapeutics, Inc., as Independent Director from 2025, Trevi Therapeutics, Inc., as Independent Director from 2023, and K36 Therapeutics, Inc., as Director.
Mr. Heffernan also formerly worked at Phymatrix Corp., as Chairman, President & Chief Executive Officer from 1999 to 2002, Astellas Institute for Regenerative Medicine, as Chairman from 2013 to 2016, CTx Operations, Inc., as Chairman, Veloxis Pharmaceuticals A, as Chairman from 2016 to 2020, TYRX, Inc., as Director, Cornerstone BioPharma, Inc., as Director in 2008, Akebia Therapeutics, Inc., as Independent Director from 2018 to 2022, Cornerstone Therapeutics, Inc., as Independent Director from 2011 to 2014, Biohaven Pharmaceutical Holding Co. Ltd., as Independent Director from 2020 to 2021, Keryx Biopharmaceuticals, Inc., as Independent Director from 2016 to 2018, Synlogic, Inc., as Independent Director from 2020 to 2025, and Eli Lilly & Co., as Principal.
Mr. Heffernan received his undergraduate degree in 1987 from the University of Connecticut.